logo
[breadcrumb_custom]

Day: May 17, 2022

Trading Signals

Eli Lilly and Company (LLY) Becomes Attractive Again

Eli Lilly & Company (NYSE: LLY) has won clearance to market tirzepatide, a medicine that has the potential to change diabetes treatment. On May 17, LLY stock rose 2.66 percent to $299.38 in trading. Experts from the US Food and Drug Administration (FDA) agreed that tirzepatide is sufficiently effective and safe for therapeutic usage based on the findings of the third phase of clinical research. The medicine reduced blood sugar levels more effectively than currently available medications.  Eli Lilly gained authorization to commercialize tirzepatide as an addition to a healthy diet and physical activity program for persons with type 2